INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 176 participants.
Also called NCT03539302
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 176 participants
- Sponsor
- InCarda Therapeutics, Inc.
- Registry
-
NCT03539302
-
- Other papers using this trial's data
- Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Belgium, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT03539302. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-29 (actual); primary completion 2022-01-17 (actual). Results posted on 2024-05-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
- Acronym
- INSTANT
- Condition
- Paroxysmal Atrial Fibrillation (PAF)
- Intervention (Drug)
- Flecainide Acetate
- Lead sponsor
- InCarda Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03539302- Content hash
74454af2f9c63c0360716d15dcceff1203ccd8b4cf1e81ccbed3e53a18cd9431